Table of Contents

State/Territory Name: North Carolina

State Plan Amendment (SPA) #: 21-0008

This file contains the following documents in the order listed:

- 1) Approval Letter
- 2) CMS 179 Form/Summary Form
- 3) Approved SPA Pages

DEPARTMENT OF HEALTH & HUMAN SERVICES Centers for Medicare & Medicaid Services 7500 Security Boulevard, Mail Stop S2-14-26 Baltimore, Maryland 21244-1850



Center for Medicaid and CHIP Services

Disabled and Elderly Health Programs Group

July 16, 2021

Dr. Mandy Cohen, MD, MPH
Secretary, North Carolina Medicaid
Office of the Secretary
NC Department of Health and Human Services
2001 Mail Service Center
Raleigh, North Carolina 27699-20014

Dear Dr. Cohen:

The CMS Division of Pharmacy team has reviewed North Carolina's State Plan Amendment (SPA) 21-0008 received in the CMS Medicaid & CHIP Operations Group on April 26, 2021. This SPA proposes to allow North Carolina to include Medicaid MCO drug utilization in the collection of State Supplemental Drug Rebate.

Based on the information provided and consistent with the regulations at 42 CFR 430.20, we are pleased to inform you that SPA 21-0008 is approved with an effective date of July 1, 2021. We are attaching a copy of the signed, updated CMS-179 form, as well as the pages approved for incorporation into North Carolina's state plan.

If you have any questions regarding this amendment, please contact Charlotte Amponsah at (410) 786-1092 or charlotte.amponsah@cms.hhs.gov.

Sincerely,

cc: Dave Richard, Deputy Secretary, NC Medicaid Betty Staton, North Carolina State Plan and Amendments Manager State: NORTH CAROLINA

12.a. <u>Prescribed Drugs (continued)</u>

- (4) DESI drugs and any identical, similar or related products or combinations of these products are not covered.
- (5) Supplemental Medicaid Drug Rebate Agreements

A rebate agreement between the State and a drug manufacturer for drugs provided to the Medicaid population, submitted to CMS on December 30, 2009 and entitled, "State of North Carolina Magellan Medicaid Administration National Medicaid Pooling Initiative (NMPI)," has been authorized by CMS.

The State assures compliance with Section 1927 of the Social Security Act. Drugs of federal rebate participating manufacturers are covered. Policies for the supplemental rebate program for Medicaid beneficiaries are as follows:

- a) Supplemental rebates received by the State in excess of those required under the national drug rebate agreement will be shared with the Federal government on the same percentage basis as applied under the national rebate agreement.
- b) Supplemental rebates are for the Medicaid population only and will be collected from manufacturers based on drug utilization for both fee-for-service and managed care plan participants effective July 1, 2021.
- c) The State will be negotiating supplemental rebates in addition to the federal rebates provided for in Title XIX. Rebate agreements between the State and a pharmaceutical manufacturer will be separate from the federal rebates.
- d) All drugs covered by the program, irrespective of placement on the recommended drug list, will comply with the provisions of the national drug rebate agreement.
- e) The State is in compliance with reporting requirements for utilization and restrictions to coverage. Pharmaceutical manufacturers may audit utilization data. The unit rebate amount is confidential and cannot be disclosed for purposes other than rebate invoicing and verification.
- f) Participation in the Magellan Medicaid Administration National Medicaid Pooling Initiative (NMPI) will not limit the State's ability to negotiate state-specific supplemental rebate agreements for specific drug classes that are not part of the NMPI. These agreements must be authorized by CMS.

TN No.: <u>21-0008</u>
Supersedes Approval Date: <u>7/16/2021</u> Effective Date: <u>07/01/2021</u>
TN. No.: <u>13-042</u>